medigraphic.com

2020, Number 1

<< Back Next >>

Enf Infec Microbiol 2020; 40 (1)

Staphylococcemia mortality: influence of methicillin resistance and site of infection acquisition in a patient’s cohort from Medellin, Colombia

Hincapié C, Galeano JA, Tibaduiza MF, Restrepo CA, Garcés D, Caraballo C, Echeverri L, Ascuntar J, León AL, Jaimes FA

Language: Spanish
References: 31
Page: 8-15
PDF size: 263.75 Kb.


ABSTRACT

Methicillin-resistant Staphylococcus aureus bacteraemia (MRSA) incidence seems to be increasing in some countries. This phenomenon has also been detected in Colombia.
Objective. To estimate the potential interaction between the place of acquisition of the infection and antimicrobial resistance, in hospital lethality of patients with S. aureus bacteremia.
Methods. Patients retrospective cohort with microbiological isolation for S. aureus. The information related to the episode was recorded. The effect interaction was estimated with a stratified analysis of Mantel-Hanzel.
Results. 1 201 patients were included, median age 57 years (IQR = 42-69). In 540 (45%) they had nosocomial bacteraemia, 24.4% of them (n = 292) were MRSA. In 301 (25%) bacteraemia of the community, the frequency of MRSA was 25.6% (n = 77). Mortality was 25.7% (n = 139) for nosocomial bacteraemia and 30.6% (n = 92) for community bacteraemia. No differences were found in hospital mortality due to mrsa or S. aureus meticilino sensible (SASM). In the stratified analysis, no differences were found in the risk of death of SARM vs. SASM according to the place of acquisition (p = 0.36). Hospital mortality was different (p ‹0.0001) according to the acquisition of infection in the community (30.6%), hospital (25.7%) or associated with health care (16.4%).


REFERENCES

  1. Naves, K.S., Vaz da Trindade, N. y Gontijo Filho, P.P., “Methicillin-resistant Staphylococcus aureus bloodstream infection: risk factors and clinical outcome in nonintensive- care units”, Rev Soc Bras Med Trop, 2012, 45 (2): 189-193.

  2. Rehm, S.J. y Tice, A., “Staphylococcus aureus: methicillin- susceptible S. aureus to methicillin-resistant S. aureus and vancomycin-resistant S. aureus, Clin Infect Dis, 2010, 51, Suppl 2: S176-182.

  3. Albur, M.S., Bowker, K., Weir, I. y MacGowan, A., “Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia”, Eur J Clin Microbiol Infect Dis, 2012, 31 (3): 295-301.

  4. Shorr, A.F., Kunkel, M.J. y Kollef, M., “Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies”, J Antimicrob Chemother, 2005, 56 (5): 923-929.

  5. García-Vázquez, E., Gómez, J., Baños, R., Canteras, M., Ruiz, J., Baños, V. et al., “A comparative study of patients with methicillin susceptible versus methicillin resistant Staphylococcus aureus bacteremia: epidemiology and prognostic factors”, Med Clin, 2007, 128 (18): 681-686.

  6. Ministerio de Salud y Protección Social, Dirección de Medicamentos y Tecnologías en Salud, Plan nacional de respuesta a la resistencia a los antimicrobianos, 2018. Disponible en: https://www.minsalud.gov.co/sites/rid/ Lists/BibliotecaDigital/RIDE/VS/MET/plan-respuestaresistencia- antimicrobianos.pdf.

  7. Paul, M., Kariv, G., Goldberg, E., Raskin, M., Shaked, H., Hazzan, R. et al., “Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia”, J Antimicrob Chemother, 2010, 65 (12): 2658-2665.

  8. Lodise, T.P., McKinnon, P.S., Swiderski, L. y Rybak, M.J., “Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia”, Clin Infect Dis, 2003, 36 (11): 1418-1423.

  9. Jiménez-Quiceno, J.N. y Correa-Ochoa, M.M., “Staphylococcus aureus resistente a meticilina: bases moleculares de la resistencia, epidemiología y tipificación”, iatreia, 2009, 22 (2): 147-158.

  10. Baba, T., Takeuchi, F., Kuroda, M., Yuzawa, H., Aoki, K., Oguchi, A. et al., “Genome and virulence determinants of high virulence community acquired mrsa”, Lancet, 2002, 359: 1819-1827.

  11. Hincapié-Osorno, C., Caraballo-Cordovez, C., Tibaduiza- García, M.F., Garcés-Rodríguez, D., Echeverri-Toro, L., Ascuntar-Tello, J. et al., “Caracterización clínica y microbiológica de la bacteriemia por Staphylococcus aureus, Acta Med Colomb, 2018, 43 (4): 200-206.

  12. Charlson, M.E., Pompei, P., Ales, K.L. y MacKenzie, C.R., “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation”, Journal of Chronic Diseases, 1987, 40 (5): 373-383.

  13. Friedman, N.D., Kaye, K.S., Stout, J.E., McGarry, S.A., Trivette, S.L., Briggs, J.P. et al., “Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections”, Ann Intern Med, 2002, 137 (10): 791-797.

  14. Knaus, W.A., Draper, E.A., Wagner, D.P. y Zimmerman, J.E., “apache ii: a severity of disease classification system”, Crit Care Med, 1985, 13 (10): 818-29. Epub 1985/10/01.

  15. Vincent, J.L., Moreno, R., Takala, J., Willatts, S., De Mendoça, A., Bruining, H. et al., “The sofa (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine”, Intensive Care Med, 1996, 22 (7): 707-710.

  16. Benichou, J., “A review of adjusted estimators of attributable risk”, Stat Methods Med Res, 2001, 10 (3): 195-216.

  17. De Rosa, F.G., Corcione, S., Motta, I., Petrolo, A., Filippini, C., Pagani, N., et al., “Risk factors for mortality in patients with Staphylococcus aureus bloodstream infection”, J Chemother, 2016, 28 (3): 187-190.

  18. Bassetti, M., Peghin, M., Trecarichi, E.M., Carnelutti, A., Righi, E., Del Giacomo, P. et al., “Characteristics of Staphylococcus aureus bacteraemia and predictors of early and late mortality”, plos One, 2017, 12 (2): e0170236.

  19. Ayau, P., Bardossy, A.C., Sánchez, G., Ortiz, R., Moreno, D., Hartman, P. et al., “Risk factors for 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infections”, Int J Infect Dis, 2017, 61: 3-6.

  20. Stefani, S., Chung, D.R., Lindsay, J.A., Friedrich, A.W., Kearns, A.M., Westh, H. et al., “Meticillin-resistant Staphylococcus aureus (mrsa): global epidemiology and harmonisation of typing methods”, Int J Antimicrob Agents, 2012, 39 (4): 273-282.

  21. Sader, H.S., Jones, R.N., Gales, A.C., Silva, J.B. y Pignatari, A.C., “The sentry Antimicrobial Surveillance Program Report: Latin American and Brazilian results for 1997 through 2001”, Braz J Infect Dis, 2004, 8 (1): 25-79.

  22. (cdc) cfdcap, “Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients: United States, 2005”, Morb Mortal Wkly Rep, 2007, 56 (9): 197-199.

  23. Rodríguez-Baños, J., Ángeles Domínguez, M., Blas Millán, A., Borraz, C., Pau González, M., Almirante, B. et al., “Clinical and molecular epidemiology of community- acquired, health care-associated and nosocomial methicillin-resistant Staphylococus aureus in Spain”, Clin Microbiol Infect, 2009, 15 (12): 1111-1118.

  24. Maldonado, N.A., Múnera, M.I., López, J.A., Sierra, P., Robledo, C., Robledo, J. et al., “Trends in antibiotic resistance in Medellin and municipalities of the Metropolitan Area between 2007 and 2012: results of six years of surveillance”, Biomedica, 2014, 34 (3): 433-446.

  25. Kallen, A.J., Mu, Y., Bulens, S., Reingold, A., Petit, S., Gershman, K. et al., “Health care-associated invasive mrsa infections, 2005-2008”, jama, 2010, 304 (6): 641-648.

  26. Tong, S.Y., Davis, J.S., Eichenberger, E., Holland, T.L. y Fowler, V.G., “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management”, Clin Microbiol Rev, 2015, 28 (3): 603-661.

  27. De Kraker, M.E., Jarlier, V., Monen, J.C., Heuer, O.E., Van de Sande, N. y Grundmann, H., “The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System”, Clin Microbiol Infect, 2013, 19 (9): 860-868.

  28. Villalobos Rodríguez, A.P., Díaz Ortega, M.H., Barrero Garzón, L.I., Rivera Vargas, S.M., Henríquez Iguarán, D.E., Villegas Botero, M.V. et al., “Trends of bacterial resistance phenotypes in high-complexity public and private hospitals in Colombia”, Rev Panam Salud Pública, 2011, 30 (6): 627-633.

  29. Kaasch, A.J., Barlow, G., Edgeworth, J.D., Fowler, V.G., Hellmich, M., Hopkins, S. et al., “Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies”, J Infect, 2014, 68 (3): 242- 251.

  30. Lee, C.C., Lee, C.H., Hong, M.Y., Tang, H.J. y Ko, W.C., “Timing of appropriate empirical antimicrobial administration and outcome of adults with community-onset bacteremia”, Crit Care, 2017, 21 (1): 119.

  31. GREBO, Resultados del proyecto Impacto clínico y económico de la resistencia bacteriana en hospitales del Distrito, Bogotá, 2010.




2020     |     www.medigraphic.com